Risankizumab for Ulcerative Colitis
2024 · JAMA · 98 citations
https://doi.org/10.1001/jama.2024.12414
R
Remo Panaccione
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
78
Papers
328
Citations
9
h-index
8
i10-index
Remo Panaccione is an academic researcher from University of Calgary. The author has contributed to research in topics: Inflammatory Bowel Disease & Microscopic Colitis & Eosinophilic Esophagitis. The author has an h-index of 9, co-authored 67 publications.
Papers by this author
worksEfficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GRAVITI Study
2025 · Gastroenterology · 33 citations
https://doi.org/10.1053/j.gastro.2025.02.033
Challenges and Opportunities in IBD Clinical Trial Design
2021 · Gastroenterology · 29 citations
https://doi.org/10.1053/j.gastro.2021.03.065
Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons
2024 · Advances in Therapy · 8 citations
https://doi.org/10.1007/s12325-024-02912-y
The Impact of the COVID-19 Pandemic on Patients with Ulcerative Colitis: Results from a Global Ulcerative Colitis Narrative Patient Survey
2023 · Advances in Therapy · 3 citations
https://doi.org/10.1007/s12325-023-02673-0
An international consensus on the design of clinical trials for advanced combination treatment (ACT) in inflammatory bowel disease
2025 · EClinicalMedicine · 2 citations
https://doi.org/10.1016/j.eclinm.2025.103582
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat